Candesartan CAS 139481-59-7 Ubunyulu > 99.0% (HPLC) Factory

Inkcazelo emfutshane:

Igama leKhemikhali: Candesartan

CAS: 139481-59-7

Ubunyulu: >99.0% (HPLC)

Imbonakalo: Umgubo oMhlophe

I-Angiotensin II Receptor Antagonist ekhethiweyo

Umgangatho ophezulu, iMveliso yoRhwebo

E-Mail: alvin@ruifuchem.com


Iinkcukacha zeMveliso

Iimveliso ezinxulumeneyo

Iithegi zeMveliso

Inkcazo:

Iipropati zeMichiza:

Igama leMchiza Candesartan
Izithethantonye I-CV-11974;I-2-Ethoxy-1-[[2'- (1H-tetrazol-5-yl) [1,1'-biphenyl] -4-yl]methyl] -1H-Benzimidazole-7-Carboxylic Acid;3- [[2'- (1H-Tetrazol-5-yl) biphenyl-4-yl]methyl]-2-ethoxy-3H-Benzimidazole-4-Carboxylic Acid;iCandesartan M1;Candesartan Cilexetil EP Ukungcola G
Inombolo yeCAS 139481-59-7
Inombolo yeCAT RF-PI1889
Ubume beStokhwe Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni
Ifomula yeemolekyuli I-C24H20N6O3
Ubunzima beMolekyuli 440.45
Uphawu Ruifu Chemical

Iinkcukacha:

Into Iinkcukacha
Imbonakalo Umgubo oMhlophe
Ukuchongwa-HPLC Ixesha lokuGcinwa lifana noMgangatho
Ukuchongwa-IR Iyafana noMgangatho
Ubunyulu / Indlela yokuHlalutya >99.0% (HPLC)
Indawo yokunyibilika 183.0 ~ 185.0℃
Ilahleko ekomisweni <0.50%
Ukufuma (KF) <0.50%
Intsalela kwi-Ignition <0.50%
Iintsimbi ezinzima <20ppm
Ukungacoceki komntu <1.00% (HPLC)
Ukungcola ngokupheleleyo <1.00% (HPLC)
Refractive Index n20/D 1.745~1.747
Umgangatho woVavanyo Umgangatho woShishino
Ukusetyenziswa API;KuNyango loxinzelelo lwegazi

Ukupakishwa kunye noGcino:

Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi

Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma

Izinto eziluncedo:

1

FAQ:

Isicelo:

I-Candesartan (i-CAS: 139481-59-7) i-angiotensin II receptor antagonist kunye ne-IC50 ye-0.26 nM.Ithagethi: I-Angiotensin II Receptor candesartan iboniswa kunyango loxinzelelo lwegazi.I-Candesartan Cilexetil yavunywa okokuqala kwi-GB ngo-Apr 29, i-1997, emva koko yamkelwa yi-US Food and Drug Administration (FDA) ngoJuni 4, 1998, kwaye yamkelwa yi-Arhente ye-Pharmaceuticals and Medical Devices Agency yaseJapan (PMDA) ngo-Mar 12, 1999. Yaphuhliswa ngu-AstraZeneca, emva koko yathengiswa njenge-Atacand ngu-AstraZeneca kwi-GB kunye ne-US, kwaye ithengiswa njengeBlopress nguTakeda kwiJP.I-Candesartan Cilexetil yi-angiotensin II receptor blocker (ARB), ivimba i-vasoconstrictor kunye nemiphumo ye-aldosterone-secreting ye-angiotensin II ngokuthintela ngokukhethekileyo ukubopha i-angiotensin II kwi-receptor ye-AT1 kwiithishu ezininzi, ezifana ne-vascular smooth muscle kunye ne-adrenal gland.I-Atacand iboniswa kunyango lwe-hypertension kubantu abadala kunye nabantwana i-1 ukuya

Bhala umyalezo wakho apha kwaye uwuthumele kuthi